RA Capital Healthcare Fund LP's Form 4 filing
Freenome, Inc. (FRNM) · filed Jul 22, 2026
- Accession no.
- 0001231919-26-000783
- Filed
- Jul 22, 2026, 5:31 PM ET
- Trade date
- Jul 20, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 7 non-derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund, L.P.CIK 0001780117 | Director |
| RA Capital Nexus Fund II, L.P.CIK 0001825376 | Director |
| RA Capital Nexus Fund III, L.P.CIK 0001883840 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | Common Stock | AGrant or awardAcquired | +6,561,711 | –F2 | – | 7,311,711 | Indirect | |
| Jul 20, 2026 | Common Stock | AGrant or awardAcquired | +970,950 | –F5 | – | 970,950 | Indirect | |
| Jul 20, 2026 | Common Stock | AGrant or awardAcquired | +553,703 | –F7 | – | 553,703 | Indirect | |
| Jul 20, 2026 | Common Stock | AGrant or awardAcquired | +908,103 | –F9 | – | 908,103 | Indirect | |
| Jul 20, 2026 | Common Stock | AGrant or awardAcquired | +367,427 | –F11 | – | 367,427 | Indirect | |
| Jul 20, 2026 | Common Stock | AGrant or awardAcquired | +4,918,411 | $10.00 | +$49,184,110 | 12,230,122 | Indirect | |
| Jul 20, 2026 | Common Stock | AGrant or awardAcquired | +336,965 | $10.00 | +$3,369,650 | 1,245,068 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Received in the Business Combination in exchange for 4,886,446 shares of Series B Preferred Stock, 4,111,335 shares of Series C Preferred Stock, 4,093,925 shares of Series D Preferred Stock and 10,103,180 shares of Series F Preferred Stock of Old Freenome.
Referenced by the price of 1 transaction in Table I.
- F5
Received in the Business Combination in exchange for 1,920,093 shares of Series B Preferred Stock and 1,512,104 shares of Series C Preferred Stock of Old Freenome.
Referenced by the price of 1 transaction in Table I.
- F7
Received in the Business Combination in exchange for 1,754,539 shares of Series D Preferred Stock and 202,739 shares of Series F Preferred Stock of Old Freenome.
Referenced by the price of 1 transaction in Table I.
- F9
Received in the Business Combination in exchange for 3,210,040 shares of Series F Preferred Stock of Old Freenome.
Referenced by the price of 1 transaction in Table I.
- F11
Received in the Business Combination in exchange for 873,834 shares of Series B Preferred Stock and 424,978 shares of Series C Preferred Stock of Old Freenome.
Referenced by the price of 1 transaction in Table I.
Remarks
Dr. Peter Kolchinsky, a Managing Partner of the Adviser, serves on the Issuer's board of directors.